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Introduction: Regional therapy with trans-arterial chemoembolization (TACE) is a common treatment for
unresectable hepatocellular carcinoma (HCC). Outcomes were examined in patients with the best radio-
logical response (BR) after the initial TACE.
Methods: This was a retrospective cohort study of patients who underwent TACE as the initial treatment
for HCC between the years 2000 and 2010. BR was defined as complete disappearance of the tumour
or no enhancement with contrast on the first cross-sectional imaging study after the initial TACE.
Results: Seventy-eight out of 104 total consecutive patients were identified with the potential for a BR
to TACE therapy for unresectable HCC, and 24 met the criteria for BR. Patients with BR had a median
survival of 12.8 months (2.2–54.9) compared with 18.9 months(1.3–56.7) for the entire cohort (P = 0.313).
The median time to progression was 10.6 months (1.2–24.3) in the BR group and 3.2 months (0.7–49.2)
in the patients without a BR (P = 0.003).
Discussion: BR to initial TACE for unresectable HCC is associated with comparable survival to those
without BR in spite of a longer time to cancer progression. It may be reasonable to consider further
therapy such as repeat TACE or biological/systemic therapy in patients with HCC even when the
radiological response to the initial TACE is favourable.
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Introduction
Liver cancer has a devastating global impact being the third
leading cause of cancer-related death worldwide. Hepatocelluar
carcinoma (HCC) compromises 70–85% of liver cancer diagnoses
resulting in well over 500 000 deaths worldwide each year.1,2 While
this disease is most prevalent in the African and Asian continents,
its incidence is on the rise in the United States with liver cancers as
a whole being the fastest growing group of cancers over the past
decade.1,3 In spite of the prevalence of this disease treatment
options are limited resulting in a 1-year survival rate of less than
50% for all stages worldwide.3,4
Potentially curative treatment with surgical resection or
transplantation is limited to a small subset of HCC patients.3,5
Many patients are not candidates for these procedures because of
advanced cirrhosis precluding safe resection or tumours outside
transplant criteria.5 While other options such as local ablative
therapy are available these are limited by the extent of cirrhosis
and the size and location of tumour(s).6 Therefore a commonly
used treatment for HCC in the presence of cirrhosis is trans-
arterial chemoemboization (TACE).7 TACE has been shown to be
safe and improve survival in patients with unresectable HCC
compared with no therapy or best supportive care.8–11 As expected
outcomes are best in patients with compensated or Child’s A
cirrhosis, TACE has also been used by some in properly selected
patients with more advanced cirrhosis.12 Favourable outcomes
from TACE are associated with Child’s Class A cirrhosis13 lack of
ascites,13 age younger than 60 years,14 alkaline phosphatase less
than 120 U/l,14albumin greater than 35 g/l,14 smaller tumours,15
solitary tumours,15 good baseline performance status,16 low bil-
lirubin level,7,16 and multiple TACE procedures.15,16
A best or complete radiological response to TACE has been
defined as a lack of contrast enhancement on imaging after the
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procedure.7,15–18 Such a best response to TACE has been associated
with improved survival in patients with recurrent HCC after a
hepatectomy15 and in patients with class A and B cirrhosis.7,16 Of
note, some of these previous studies allowed for multiple serial
TACE procedures to be done in order to achieve a best response
after the final TACE.7,15,16 One study by Imai suggested that a
favourable response after subsequent TACE is associated with the
response seen at previous TACE procedures (not specifically the
initial TACE), but the present study did not examine survival
outcomes based upon response.17 In this study, outcomes for
individuals having a best response (BR) after initial TACE for
unresectable HCC are compared with the individuals who do
not have a BR.
Methods
After Institutional Review Board approval, the medical records of
104 patients with unresectable HCC treated with initial TACE
therapy between 2000 and 2010 were reviewed. All patients had
the diagnosis of HCC made by characteristic radiographical find-
ings on pre-procedure liver magnetic resonance imaging (MRI) or
computed tomography (CT); ultrasound or a CT-guided biopsy
was done if tumour features were suggestive, but not diagnostic
for HCC. Patients with extra-hepatic disease or major vascular
invasion were excluded. Patients without post-TACE imaging
were also excluded.
TACE therapy was generally offered to patients with unresect-
able HCC, Child’s class A or B cirrhosis, an Eastern Cooperative
Oncology Group performance status of 0–2, no encephalopathy
and no ascites detectable on physical examination. Very rarely,
patients with Child’s C cirrhosis were offered TACE. TACE
therapy was triple drug TACE (cisplatin 50 mg, doxorubicin
30 mg, and mitomycin C 20 mg with Visipaque at 320 mg/ml)
using a 10-ml Lipiodol carrier and most of the procedures tar-
geted the right or left lobar distribution. After 2009, LC Beads
(coated with 100 mg of doxorubicin) (Biocompatibles, Farnham,
Surrey, UK) were used for all TACE procedures in any patient with
HCC. Some patients received bland embolization. Most patients
were discharged the day after TACE. A physical examination and
laboratory studies were conducted within a few days after dis-
charge from the initial hospitalization in the outpatient setting.
Liver protocol CT or MRI was done around 1 to 2 months after
TACE, and if no further therapy was needed, surveillance imaging
and labs were repeated every 3 months for the first year then every
6 months for at least another 2 years.
A radiological BR to TACE therapy was determined using the
first imaging study available at least 2 weeks after the initial TACE
therapy. Both abdominal contrast-enhanced MRI and multiphase
CT were allowed. BR was defined as no abnormal enhancement or
density consistent with a viable tumour present at the previous
target site(s) for TACE or complete disappearance of tumour(s)
after the initial TACE without any new tumours within the liver
or abdomen concerning early progression. For the patients that
received Lipiodol, areas of enhancement that had washout or
obvious tumour lesions without Lipiodol contrast were consid-
ered to have a residual tumour. If a patient had additional TACE
therapy less than 2 months after the intial TACE, they were con-
sidered to not have a BR.
Clinical tumour characteristics and outcomes were compared
between those with BR after the initial TACE for unresectable
disease to those without BR using Student’s t-test for parametric,
continuous data, Mann–Whitney U-test for non-parametric, con-
tinuous data, and Fisher’ exact test for all nominal data. From data
obtained through the chart review, the Child–Pugh score, model
of end-stage liver disease (MELD) score, and TACE survival
score14 were calculated for each patient. Overall survival was
defined as the time from initial TACE therapy to date of death or
censored at last follow-up. Time to progression was defined as the
time from the initial TACE to the first sign of progression after
TACE. Kaplan–Meier curves were used to compare groups and
significance was determined by the log-rank test. Factors were
considered to be associated with overall survival when a P-value of
less than 0.05 was obtained by univariate analysis. All statistics
were performed using Statistical Package for Social Sciences
(SPSS) Version 19 (SPSS Inc., Chicago, IL, USA).
Results
There were 104 patients who underwent TACE for initial treat-
ment of unresectable HCC between 2000 and 2010. A total of 26
(25%) patients were excluded from the analysis. Seven had extra-
hepatic disease, five had major vascular invasion and two had a
combination of these findings on pre-procedure imaging. Twelve
patients did not have post-TACE imaging owing to the following
reasons: six died in less than 2 months after the TACE procedure,
one was assumed to need additional TACE procedures without
imaging because of the size of the original tumour, one had a
secondary malignancy discovered that prioritized their therapy,
one had a brain metastasis discovered after the procedure that
altered the plan of therapy, one patient had a liver transplant and
two had reasons that were unknown. Of the remaining patients,
24 (30.8%) met the criteria for BR whereas 54 (79.2%) did not
have BR (Fig. 1). A small number of patients in the study (n = 11)
underwent TACE for recurrent HCC after previous potentially
curative ablation or surgical resection; none of these recurrences
were local. There were no significant differences in patient demo-
graphics between patients in the BR group and the remaining
portion of the TACE cohort who did not have a BR. A difference
was observed in the synthetic liver function between the groups,
but not any other lab values. All patients had liver cirrhosis and
the degree of liver impairment was not significantly different
between the two groups (Table 1).
Baseline tumour characteristics were similar between the two
groups. (Table 2). There was no statistical difference in the type or
specifity of the TACE therapy used between those with BR and
those without, and alpha-feto protein (AFP) levels before and
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after TACE were not different (Table 2). The pre-TACE imaging
was performed at this institution for 63 (80.8%) of the patients
and all patients had post-TACE imaging performed at this hospi-
tal. Imaging was generally obtained at a median of 52 days (15–
810) after the initial TACE. The median length of hospital stay was
2 days (1–15) in the entire cohort and 2 days in both the non-BR
(1–6 days) and the BR groups (1–15 days) (P = 0.160). Only one
60-day mortality occurred in the entire cohort and that was in the
non-BR group. There were three patients who experienced major
complications in the BR group compared with 15 in the non-BR
group (P = 0.160). Common complications included infection,
hepatic insufficiency and gastrointestinal bleeding. There were
three with hepatic failure in the non-BR group and two with
hepatic failure in the BR group (P = 0.641).
Progression of disease occurred in 69 of the 78 (82.2%) patients
within the cohort. In the BR group, 17 out of 24 had progression
of disease compared with 52 of the 54 within the non-BR group.
The median time to progression (TTP) after the initial TACE was
4.6 months (0.7–54.9) in the entire cohort, and the BR group
experienced a median TTP of 10.6 months (1.2–54.9) compared
(a) Pre- Tace Post- Tace
A
(b)
ecaT-tsoPecaT-erP
Figure 1 (a) An example of a best response: this is a computed tomography (CT) image from a 76-year-old woman who presented with
haemoperitoneum from a bleeding left lateral segment hepatocellular carcinoma (HCC) (arrow, left CT). Multiple comorbidities and portal
hypertension made surgical resection not feasible therefore she was treated with trans-arterial chemoembolization (TACE). A CT scan
performed 1 month after the initial TACE revealed no evidence of a residual viable tumour (arrow right CT). Several more serial CT scans
showed no evidence of a mass until she developed local recurrence/progression 2 years after the initial TACE. (b) An example of not a best
response: magnetic resonance imaging (MRI) images are shown from a patient with cirrhosis and three arterial-enhancing tumours in the
right liver (arrows, left MRI) treated with TACE. MRI images obtained approximately 1 month after TACE revealed a tumour response with
overall loss of enhancement but some residual peripheral enhancement around two of the masses (arrows, right MRI)
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with 3.2 months (0.7–49.2) in the non-BR group (P = 0.003,
Fig. 2). The most common site of progression was an intrahepatic
tumour in both groups (n = 12 and n = 41, respectively), and the
most common therapy given for progression after the initial TACE
was another TACE (n = 8 and n = 18, respectively). Two (2.6%)
patients in the entire cohort underwent liver transplantation after
the initial TACE.
The median overall survival (OS) was 16.0 months (1.3–56.7)
after the initial TACE. In the group with BR after TACE, the
median OS was 12.8 months (2.2–54.9) compared with 18.9
months (1.3–56.7) in the remaining patients without BR (P =
0.313, Fig. 3). In the patients with compensated cirrhosis (Child’s
A), the median OS after TACE in the BR group was not different
compared with the without BR group (P = 0.675, Fig. 4). Other
factors associated with overall survival in the entire cohort
included Child’s class and MELD score (Table 3).
Discussion
After the initial TACE for HCC, a best or complete radiological
response is not a rare occurrence and can be seen in the range of
14–70% of TACE procedures for HCC.7,15–17 The TACE best
response rate of 31% in this study falls within this range, and
notably represents a response after the initial TACE whereas some
other studies with higher rates allowed for multiple TACE proce-
dures to achieve BR.15 These studies have also demonstrated that a
Table 1 Patient demographics and baseline liver function
TACE cohort (n = 78) No BR (n = 54) BR (n = 24) P-value
Age, years [median (range)] 60 (31–83) 59 (31–81) 59 (48–83) 0.380
Gender [n, (% male)] 58 (74.4) 42 16 0.400
HBV [n (%)] 9 (11.5) 8 1 0.261
HCV [n (%)] 33 (42.3) 22 11 0.805
Total bilirubin [median (range)] 1.1 (0.4–4.4) 1.0 (0.5–3.8) 1.2 (0.40–4.40) 0.173
Albumin [median (range)] 3.1 (1.5–4.9) 3.1 (1.7–4.9) 2.8 (1.5–3.7) 0.014
INR [median (range)] 1.2 (0.9–2.0) 1.2 (0.9–2.0) 1.2 (1.1–1.7) 0.042
Creatinine [median (range)] 0.82 (0.46–4.94) 0.86 (0.52–4.94) 0.79 (0.46–1.66) 0.309
Ascites [n (%)] 18 (23.1) 13 5 1.000
C-P score [median (range)] 6 (5–11) 6 (5–11) 7 (5–10) 0.071
Class A (n, %) 42 (54.8) 31 11 0.461
Class B (n, %) 34 (43.6) 23 11 0.803
Class C (n, %) 2 (2.6) 0 2 0.092
MELD score [median (range)] 9.5 (6.4–23.8) 9.1 (6.4–23.8) 9.7 (7.9–17.0) 0.059
TACE prognotic survival score [mean] 1.55 1.44 1.79 0.129
C-P, Child-Pugh; HBV, Hepatitis-B Virus; HCV, Hepatitis-C Virus; INR, International Normalized Ratio; TACE, trans-arterial chemoembolization. Bold
values indicated significant P-values in the comparison of BR to non-BR groups.
Table 2 Tumour characteristics and trans-arterial chemoembolization (TACE) treatment among the cohort
TACE cohort (n = 78) No BR (n = 54) BR (n = 24) P-value
Pre-procedure AFP level [median, (range)] 47.0 (1.3–524 000) 47.0 (1.3–524 000) 44.5 (2.0–4787) 0.830
Post-procedure AFP level [median, (range)] 24.6 (1.4–58 623) 37.6 (1.8–58 623) 23.1 (1.4–2668) 0.922
Diameter of largest tumour (cm) [median (range)] 4.4 (0.7–12.1) 4.2 (0.7–12.1) 4.8 (2.1–12.1) 0.700
More than one tumour [n (%)] 48 (61.5) 34 14 0.802
Location of tumour (s)
Right lobe [n (%)] 36 (46.2) 22 14 0.219
Left lobe [n (%)] 7 (9.0) 4 3 0.670
Bilobar [n (%)] 35 (44.8) 28 7 0.085
TACE procedure details
Selective TACE (smaller than hepatic arteries) [n (%)] 9 (11.5) 6 3 1.000
Chemotherapy TACE [n (%)] 37 (47.5) 23 14 0.227
TACE with chemo-coated beads [n (%)] 24 (30.7) 17 7 1.000
Bland TACE (embolization) [n (%)] 17 (21.8) 14 3 0.242
AFP, Alpha-feto protein.
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complete response after TACE is associated with improved
survival. While BR in this study’s patients was associated with
improved progression-free survival, outcomes were otherwise
similar between the BR and non-BR groups.
The underlying liver disease (cirrhosis) seems to influence
outcomes more than tumour stage or radiological response to
therapy in this study. Thirty-six patients (46.2%) in this study had
Child’s B or C compared with rates of 13–23% in other (mostly
prospective) studies which excluded patients with more advanced
cirrhosis.7–9,15–17 The overall survival reported in this study reflects
this inclusion of more patients with baseline poorer liver function.
In other studies similar to this one with higher rates of advanced
cirrhosis (34–63%) and survival rates range from 6–21
months.19–21 In Dhanasekaran et al. ‘s work on prognostic factors
in doxorubicin-bead TACE therapy in HCC, they found 7 out of
10 reported prognostic factors were associated with liver function
rather than tumour stage.20
The present study has several limitations. As stated, outcomes
were examined based only on radiological response to the initial
TACE. Others have found a complete or best response to correlate
with outcomes allowing for more than one TACE procedure,
and such a treatment strategy when feasible may result in better
outcomes overall. As stated above, almost half of the patients in
this study had more advanced cirrhosis. This likely explains why
only 26 out of 69 patients in the cohort with disease progression
went on to receive additional TACE therapy. It may be that com-
bination therapies or a use of selective TACE over multiple ses-
sions when feasible may improve outcomes in patients with
unresectable HCC compared with a single lobar TACE followed
by observation. The use of selective TACE has increased at this
institution since 2009. Finally, the first post-TACE imaging study
was used at a median of 52 days to determine BR or no BR, but
this may not be the ideal timing in terms of measuring this
response outcome.
In summary, the best response to the initial TACE was not
associated with a survival advantage in patients with unresectable
HCC in spite of an improved time to progression. It may be
reasonable to offer other therapies such as systemic/biological
therapy even in patients who have a favourable radiological
response to the initial TACE. A radiological response is inadequate
as a sole variable for determining prognosis in patients with HCC
who undergo regional therapy. Therefore, better molecular infor-
mation and biomarkers are needed to determine outcomes and
personalize therapies.
Figure 2 Time to progression of hepatocellular carcinoma (HCC)
after the initial trans-arterial chemoembolization (TACE) comparing
patients with a best response (BR) and those without response BR
Figure 3 Overall survival compared between patients with a best
response (BR) and without after an initial trans-arterial chemoembo-
lization (TACE) for unresectable hepatocellular carcinoma (HCC)
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